Anti-CD20 Monoclonal Antibodies Market Report 2026

Anti-CD20 Monoclonal Antibodies Market Overview

• Anti-CD20 Monoclonal Antibodies market size has reached to $9 billion in 2025 • Expected to grow to $12.94 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: The Growing Autoimmune Diseases Is Fueling The Growth Of The Market Due To Increased B-Cell Targeting Therapies For Immune Regulation • Market Trend: Advancements In Anti-CD20 Therapies For Treatment-Resistant Conditions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anti-CD20 Monoclonal Antibodies Market?

Anti-CD20 monoclonal antibodies are specialized immunotherapies that target the CD20 protein present on B-cell surfaces. These antibodies trigger immune responses such as complement activation and antibody-dependent cell-mediated cytotoxicity to eliminate abnormal or cancerous B-cells. This targeted approach enables more precise treatment with reduced systemic side effects compared to conventional chemotherapy. The main types of anti-CD20 monoclonal antibodies are rituximab, obinutuzumab, ofatumumab, and others. Rituximab is a CD20-targeting monoclonal antibody used to treat B-cell cancers and autoimmune diseases by eliminating abnormal B-cells. It is administered through different routes of administration, such as intravenous and subcutaneous, and is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is applicable in various applications such as non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris, and others and is used by several end-users, including hospitals, surgical centers and diagnostic centers, maternity centers, ambulatory care centers, research and academia, and others.

What Is The Anti-CD20 Monoclonal Antibodies Market Growth Forecast?

The anti-cd20 monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.94 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to development of obinutuzumab and ofatumumab biosimilars, increasing adoption of subcutaneous formulations, growing investment in research and academia, expansion of ambulatory care centers, increasing demand for anti-cd20 therapies in multiple autoimmune diseases. Major trends in the forecast period include rising adoption of monoclonal antibody therapies for b-cell malignancies, development of biosimilars and next-generation anti-cd20 antibodies, expansion of subcutaneous and patient-friendly administration routes, increasing focus on personalized and targeted immunotherapy, growing clinical trials and research in autoimmune and oncology indications.

Global Anti-CD20 Monoclonal Antibodies Market Segmentation

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types 2) By Route Of Administration: Intravenous, Subcutaneous 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications 5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users Subsegments: 1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux 2) By Obinutuzumab: Gazyva, Biosimilar Candidates 3) By Ofatumumab: Arzerra, Kesimpta 4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

What Is The Driver Of The Anti-CD20 Monoclonal Antibodies Market?

The growing autoimmune diseases are expected to propel the growth of the anti-CD20 monoclonal antibodies market going forward. Autoimmune diseases occur when the immune system wrongly identifies the body’s cells as threats and launches an attack against them. Autoimmune diseases are rising due to growing exposure to environmental pollutants, which can impair immune regulation and trigger attacks on the body’s tissues. Anti-CD20 monoclonal antibodies treat autoimmune diseases by eliminating B cells contributing to autoantibody production and inflammation. They help regulate the immune response and reduce disease symptoms. For instance, in February 2024, according to the Arthritis Australia, an Australia-based non-profit organization, an estimated 562,378 Australians will be living with RA in 2025, accounting for 14% of all arthritis cases that year. By 2040, this number is expected to rise by 33% to 748,721 people. This represents an additional 186,343 Australians living with RA in 2040 compared with 2025. Therefore, the growing number of autoimmune diseases is driving the growth of the anti-CD20 monoclonal antibodies industry.

Key Players In The Global Anti-CD20 Monoclonal Antibodies Market

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

Global Anti-CD20 Monoclonal Antibodies Market Trends and Insights

Major companies operating in the anti-CD20 monoclonal antibody market are focusing on developing advanced products such as obinutuzumab to target resistant or relapsed B-cell malignancies more effectively. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody designed to target and destroy CD20-positive B cells involved in certain blood cancers and autoimmune diseases. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced that the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for the treatment of lupus nephritis. It is based on positive results from the Phase III REGENCY study showing improved complete renal response (CRR) when combined with standard therapy versus standard therapy alone. It marks Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to demonstrate such benefit in lupus nephritis, a severe inflammation caused by lupus that can lead to kidney failure.

What Are Latest Mergers And Acquisitions In The Anti-CD20 Monoclonal Antibodies Market?

In August 2023, TG Therapeutics, a US-based manufacturer of anti-CD20 monoclonal antibodies, partnered with Neuraxpharm to expand global access to innovative multiple sclerosis treatment. The partnership aims to commercialize BRIUMVI (CD20‑targeted monoclonal antibody therapy) across international markets and accelerate its availability for patients with relapsing multiple sclerosis outside the U.S. Neuraxpharm is a Germany-based pharmaceutical company.

Regional Insights

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anti-CD20 Monoclonal Antibodies Market?

The anti-CD20 monoclonal antibodies market consists of sales of tositumomab, ocrelizumab, ublituximab, and mosunetuzumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-CD20 Monoclonal Antibodies Market Report 2026?

The anti-cd20 monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cd20 monoclonal antibodies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.